Answers are grounded in this paper and cite their sources.
TIL-PD-1 positivity in tumors (≥ 1%) is associated with significantly longer progression-free and overall survival after ICB. ClinicalTrials.gov ID: NCT02478931.
No takes yet. Share an insight, caveat, or question.
Bevins et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: